Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.51 EUR
Change Today +0.01 / 0.40%
Volume 69.0K
B8F On Other Exchanges
As of 4:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

biofrontera ag (B8F) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/14/14 - €3.40
52 Week Low
02/26/15 - €1.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOFRONTERA AG (B8F)

Related News

No related news articles were found.

biofrontera ag (B8F) Related Businessweek News

No Related Businessweek News Found

biofrontera ag (B8F) Details

Biofrontera AG, a biopharmaceutical company, is engaged in the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy; and Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis. The company is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a specific serotonin receptor antagonist that is in Phase I clinical trial for migraine prophylaxis. In addition, it focuses on developing Ameluz for other superficial cancer and warts. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

41 Employees
Last Reported Date: 11/13/14
Founded in 1997

biofrontera ag (B8F) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €412.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €100.0K
Compensation as of Fiscal Year 2013.

biofrontera ag (B8F) Key Developments

Biofrontera AG Provides Clinical Trials Update for its Launch of Ameluz in Belgium

Biofrontera AG has completed almost all preparations for its launch of Ameluz in Belgium. Pricing has been agreed for the Belgian market and Biofrontera anticipates that it will generate first sales in the first quarter of 2015. It is particularly beneficial that the therapy will be fully reimbursed by the Belgian health care system. An add-on payment, as is required through public health insurance in Germany, will not be required in Belgium. Distribution will be undertaken by Bipharma N.V. which is successfully distributing Ameluz in the Netherlands already. There is also notable progress in Biofrontera's other activities. During the course of this year, Ameluz will be launched in further markets in Europe. More than two thirds of the required 360 patients have been recruited in the Phase III study for the approval of basal cell carcinoma. This study is of great importance for the further growth of Biofrontera in Europe. Preparations for the FDA-filing in the USA are well progressing. All required tests, reports and documents should be finalised within the next eight weeks.

Biofrontera AG Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Biofrontera AG Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Biofrontera Launches Third Product of its Derma-Cosmetic Line Belixos

Biofrontera has launched the third product of its derma-cosmetic line Belixos®, a cooling and cleaning day care gel designed for situations of increased sebum production. Belixos® Gel was developed for the special needs of inflamed, reddened skin prone to impurities, the ideal basic care for rosacea and acne. To minimize the risk for sensitive reactions and skin irritations the gel formulation was reduced to just a few high-value ingredients. The formulation causes a cooling sensation and combines the extracts of cinnamon bark in the Sepicontrol A5 complex and mahonia aquifolium with Biofrontera's innovative Biocolloid technology. The extract of mahonia relieves inflammation, redness and itching, typical signs of rosacea. The active ingredient complex Sepicontrol A5 with cinnamon bark has antibacterial activity and removes callused skin, regulates sebum and clears congested sebaceous glands. As with the other products in the Belixos®  dermo-cosmetic series in cream and liquid formulations, the underlying biocolloid technology causes an optimized penetration of this unique ingredient combination from traditional medicinal plants extracts.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B8F:GR €2.51 EUR +0.01

B8F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B8F.
View Industry Companies

Industry Analysis


Industry Average

Valuation B8F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.8x
Price/Book 18.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOFRONTERA AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at